Complex
The complex of a modified polysaccharide with Telratolimod, encapsulated in a nanogel, addresses the systemic administration challenges of TLR7/8 agonists by enhancing solubility and reducing toxicity, achieving effective cancer therapy through enhanced macrophage polarization and immune response.
Patent Information
- Application Number
- PCT/JP2024/019982
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-21
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-05
AI Technical Summary
General TLR7/8 agonists, such as Telratolimod, face challenges with excessive cytokine release and bone marrow toxicity when administered systemically, limiting their use due to poor water solubility and systemic administration issues.
A complex comprising a modified polysaccharide with a hydrophobic group and a compound represented by general formula (1), specifically encapsulated in gel particles, enhances solubility and reduces toxicity, allowing for systemic administration by forming a nanogel with pullulan and a sterol skeleton, thereby improving macrophage polarization from M2-like to M1-like.
The formulation significantly increases the persistence and concentration of Telratolimod in the bloodstream and tumors, enhances antitumor effects, suppresses cytokine release, and reduces bone marrow toxicity, leading to effective cancer therapy with improved macrophage polarization and immune response.
Smart Images

Figure JPOXMLDOC01-APPB-C000001 
Figure JPOXMLDOC01-APPB-C000002 
Figure JPOXMLDOC01-APPB-C000003
Abstract
Description
Complex
[0001] The present invention relates to a composite.
[0002] The importance of immune cells present in cancer tissue, particularly macrophages (tumor-associated macrophages, or TAMs), has been pointed out as a factor that determines the malignancy of cancer. When TAMs are predominantly M2-like, they act immunosuppressively, creating a microenvironment favorable for cancer growth. Changing this to M1-like dominance is expected to have an inhibitory effect on cancer growth.
[0003] It has been reported that Toll-like receptor 7 and Toll-like receptor 8 (TLR7 and TLR8) activators polarize macrophages from M2-like to M1-like. In addition, various compounds are known to be TLR7 and TLR8 activators currently under development (Non-Patent Document 1).
[0004] Expert Opin Drug Discov. 2021 Aug;16(8):869-880.
[0005] Systemic administration of conventional TLR7 / 8 agonists poses the problems of excessive cytokine release and bone marrow toxicity, making them unsuitable for systemic administration. In particular, compounds of the general formula (1) described below, such as telratolimod, have relatively long hydrocarbon chains and are therefore poorly soluble in water. Furthermore, during the course of research, the inventors discovered through formulation studies that telratolimod also exhibits excessive cytokine release and bone marrow toxicity.
[0006] An objective of the present invention is to provide a technology that suppresses excessive cytokine release and bone marrow toxicity of various TLR7 / 8 activators and enables systemic administration.
[0007] In view of the above-mentioned problems, the present inventors have conducted extensive research into various TLR7 / 8 agonists and have found that the above-mentioned problems can be solved by a complex containing a modified polysaccharide having a hydrophobic group and a compound represented by general formula (1). Based on this finding, the present inventors have conducted further research and have completed the present invention. That is, the present invention encompasses the following aspects.
[0008] Item 1. A modified polysaccharide containing a hydrophobic group and a polysaccharide represented by general formula (1):
[0009]
[0010] [In the formula: R 1 R represents a linear alkyl group having 12 to 25 carbon atoms. 2 R represents a linear alkyl group having 2 to 8 carbon atoms. 3 represents a linear alkylene group having 2 to 8 carbon atoms.]
[0011] Item 2. The complex according to Item 1, wherein the constituent polysaccharide of the modified polysaccharide comprises pullulan.
[0012] Item 3. The complex according to Item 1 or 2, wherein the hydrophobic group comprises a hydrophobic group having a sterol skeleton.
[0013] Item 4. The complex according to any one of Items 1 to 3, wherein the weight-average molecular weight of the modified polysaccharide is 5,000 to 2,000,000.
[0014] Item 5. Said R 1 is a linear alkyl group having 15 to 19 carbon atoms, and 2 is a linear alkyl group having 3 to 5 carbon atoms, and the R 3 Item 5. The composite according to any one of Items 1 to 4, wherein is a linear alkylene group having 3 to 5 carbon atoms.
[0015] Item 6. The conjugate according to Item 5, wherein the compound is telratolimod.
[0016] Item 7. The composite according to any one of Items 1 to 6, which is a gel particle.
[0017] Item 8. The composite according to Item 7, wherein the compound is contained inside the gel particle.
[0018] Item 9. The complex according to any one of Items 1 to 8, wherein the mass ratio of the modified polysaccharide to the compound (mass of modified polysaccharide / mass of compound) is 2 to 20.
[0019] Item 10. The complex according to any one of Items 1 to 9, which has a scattering intensity average particle size of 10 to 200 nm.
[0020] Item 11. A medicine containing the conjugate according to any one of Items 1 to 10.
[0021] Item 12. The pharmaceutical agent according to Item 11, which is a cancer therapeutic agent.
[0022] Item 12A: A method for treating cancer, comprising administering the conjugate according to any one of Items 1 to 10 to a subject (for example, a subject having cancer).
[0023] Item 12B: The conjugate according to any one of Items 1 to 10 for use in treating cancer.
[0024] Item 12C: Use of the conjugate according to any one of Items 1 to 10 for the production of a cancer therapeutic agent.
[0025] Item 12D: Use of the conjugate according to any one of Items 1 to 10 as a cancer therapeutic agent.
[0026] Item 13. The pharmaceutical agent according to Item 11 or 12, which is a macrophage polarization agent.
[0027] Item 13A: A method for macrophage polarization, comprising administering the complex according to any one of Items 1 to 10 to a subject (for example, a subject with cancer).
[0028] Item 13B: The complex according to any one of Items 1 to 10 for use in macrophage polarization.
[0029] Item 13C: Use of the complex according to any one of Items 1 to 10 for the production of a macrophage polarization agent.
[0030] Item 13D: Use of the complex according to any one of Items 1 to 10 as a macrophage polarization agent.
[0031] Item 14. The conjugate according to any one of Items 1 to 10 or the medicament according to any one of Items 11 to 13, which is used in combination with an immune checkpoint inhibitor.
[0032] According to the present invention, it is possible to provide a pharmaceutical composition relating to an antitumor agent or the like that suppresses the excessive cytokine release and bone marrow toxicity of TLR7 / 8 agonists and that allows for systemic administration.
[0033] The results of Test Example 4 are shown. The vertical axis indicates the serum Telratolimod concentration, and the horizontal axis indicates the time elapsed since administration of the test drug. The legend indicates the test drug; "Naked Telratolimod" refers to the test drug not encapsulated in cholesterol-modified pullulan nanogel (hereafter referred to as CHP nanogel), and "CHP:Telratolimod" refers to the test drug coated with CHP nanogel. The results of Test Example 5 are shown. The vertical axis indicates the Telratolimod concentration in the tumor, and the horizontal axis indicates the test drug added. The results of Test Example 6 are shown. The vertical axis indicates the tumor volume, and the horizontal axis indicates the number of days elapsed since intradermal transplantation of cancer cells, with day 0 being the day. The legend indicates the test drug. The results of Test Example 7 are shown. The graph on the left shows the results of measurement of M1-like macrophages (vertical axis), and the graph on the right shows the results of measurement of M2-like macrophages (vertical axis). The horizontal axis indicates the test drug added. "No treatment" indicates the case without addition. The results of Test Example 8 are shown. The graph information shows the measured cytokines. The vertical axis shows the cytokine concentration in the serum, and the horizontal axis shows the test drug administered. The results of Test Example 9 are shown. RET stands for reticulocytes. The graph on the left shows the measurement results of the ratio of reticulocyte count to total red blood cells (vertical axis: %), and the graph on the right shows the blood concentration of reticulocyte count (vertical axis: x10 4 1 shows the measurement results of tumor volume (μg / μL). 1 shows the results of Test Example 10. The vertical axis indicates tumor volume, and the horizontal axis indicates the number of days since the day cancer cells were intradermally implanted, which is set to day 0. The legend indicates the test drug. 1 shows the results of Test Example 11. The vertical axis indicates tumor volume, and the horizontal axis indicates the number of days since the day cancer cells were intradermally implanted, which is set to day 0. The legend indicates the test drug. 1 shows the results of Test Example 15. The vertical axis indicates the infiltration ratio of CD8-positive T cells and NK cells into the tumor, and the horizontal axis indicates the test drug added. 1 shows the results of Test Example 16. 1 shows the results of Test Example 17. The vertical axis indicates tumor volume, and the horizontal axis indicates the number of days since the day cancer cells were intradermally implanted, which is set to day 0. The legend indicates the test drug.
[0034] In this specification, the expressions "contain" and "comprise" include the concepts of "contain", "include", "consist essentially of" and "consist only of".
[0035] 1. Conjugate In one aspect, the present invention relates to a modified polysaccharide containing a hydrophobic group and a conjugate represented by the general formula (1):
[0036]
[0037] The present invention relates to a complex (sometimes referred to as the "complex of the present invention" in this specification) containing a compound represented by the formula:
[0038] The compounds represented by general formula (1) are as follows:
[0039] In general formula (1), R 1 represents a linear alkyl group having 12 to 25 carbon atoms. The linear alkyl group preferably has 14 to 23 carbon atoms, more preferably 14 to 21 carbon atoms, even more preferably 15 to 19 carbon atoms, still more preferably 16 to 18 carbon atoms, and particularly preferably 17 carbon atoms.
[0040] In general formula (1), R 2 represents a straight-chain alkyl group having 2 to 8 carbon atoms. The straight-chain alkyl group preferably has 2 to 6 carbon atoms, more preferably 3 to 5 carbon atoms, and particularly preferably 4 carbon atoms.
[0041] In general formula (1), R 3 represents a straight-chain alkylene group having 2 to 8 carbon atoms. The straight-chain alkylene group preferably has 2 to 6 carbon atoms, more preferably 3 to 5 carbon atoms, and particularly preferably 4 carbon atoms.
[0042] The compound represented by the general formula (1) is particularly preferably telratolimod (R 1 is a linear alkyl group having 17 carbon atoms, and R 2 is a linear alkyl group having 4 carbon atoms, and R 3 is a linear alkylene group having 4 carbon atoms).
[0043] The compound represented by general formula (1) can be in the form of a salt. The salt is not particularly limited as long as it is a pharmaceutically acceptable salt, and can be, for example, an acid addition salt. Specific examples of such salts include acid addition salts with mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, malic acid, tartaric acid, fumaric acid, succinic acid, lactic acid, maleic acid, citric acid, methanesulfonic acid, trifluoromethanesulfonic acid, and ethanesulfonic acid; and acidic amino acids such as aspartic acid and glutamic acid.
[0044] The compound represented by formula (1) may be in the form of a solvate. The solvate is not particularly limited as long as it is a pharmaceutically acceptable salt, and examples thereof include solvates with solvents such as water, ethanol, glycerol, and acetic acid.
[0045] As the compound represented by the general formula (1), commercially available products can be used, or products obtained according to known production methods can be used.
[0046] The compound represented by general formula (1) may be a single type or a combination of two or more types.
[0047] The modified polysaccharide is not particularly limited as long as it is a compound obtained by modifying a polysaccharide and contains a hydrophobic group as a modifying group. In the present invention, it has been found that the poor solubility of the compound of general formula (1) in water can be improved by conjugating it with a modified polysaccharide, and furthermore, the excessive cytokine release and bone marrow toxicity of the compound of general formula (1) can be suppressed.
[0048] The polysaccharides constituting the modified polysaccharides (i.e., the polysaccharides before modification) are not particularly limited as long as they are polymers in which sugar residues are glycosidicly linked. Examples of sugar residues constituting the polysaccharides include monosaccharides such as glucose, mannose, galactose, and fucose, as well as residues derived from sugars such as disaccharides and oligosaccharides. The sugar residues may be 1,2-, 1,3-, 1,4-, or 1,6-glycosidic bonds, and the bonds may be either α- or β-type bonds. Furthermore, the polysaccharides may be either linear or branched. Glucose residues are preferred as sugar residues, and examples of polysaccharides include natural or synthetic pullulan, mannan, dextran, amylose, and amylopectin. Among these, from the viewpoints of improving poor solubility, suppressing excessive cytokine release and bone marrow toxicity, anticancer activity, macrophage polarization activity, etc., pullulan, mannan, dextran, etc. are preferably used, more preferably pullulan, mannan, etc., and particularly preferably pullulan, etc.
[0049] The weight-average molecular weight of the polysaccharide is not particularly limited as long as the modified polysaccharide can form gel particles, but is, for example, 5,000 to 2,000,000, preferably 10,000 to 1,000,000, more preferably 20,000 to 500,000, even more preferably 40,000 to 250,000, and still more preferably 80,000 to 125,000.
[0050] As the polysaccharide, commercially available products can be used, or products obtained according to known production methods can be used.
[0051] The hydrophobic group is not particularly limited as long as it is a group having hydrophobicity. From the viewpoints of improving poor solubility, suppressing excessive cytokine release and bone marrow toxicity, anticancer activity, macrophage polarization activity, etc., preferred examples of the hydrophobic group include a hydrophobic group having a sterol skeleton and a hydrocarbon group, and particularly preferred examples include a hydrophobic group having a sterol skeleton.
[0052] The sterol skeleton is an alcohol with a hydroxy group bonded to a cyclopentahydrophenanthrene ring as shown in formula (I). The symbols A to D in formula (I) represent the individual rings that make up the cyclopentahydrophenanthrene ring.
[0053]
[0054] The sterol skeleton may have a double bond in the cyclopentahydrophenanthrene ring, and the position of the hydroxyl group is not particularly limited. Sterols having a hydroxyl group bonded to the C-3 position and a double bond in the B ring, or stanols having a hydroxyl group bonded to the C-3 position and a saturated ring, are preferred. Examples of hydrophobic groups having a sterol skeleton include groups derived from compounds in which the sterol skeleton is modified, for example, by substituting a hydrocarbon group (e.g., a linear or branched alkyl group having 1 to 20 carbon atoms) at a ring carbon atom. Here, the term "derived group" refers to a group obtained by removing a functional group such as a hydrogen atom or a hydroxyl group from a compound.
[0055] Examples of the hydrophobic group having a sterol skeleton include a cholesterol-derived group, a cholestanol-derived group, a lanosterol-derived group, an ergosterol-derived group, a β-sitosterol-derived group, a campesterol-derived group, a stigmasterol-derived group, a brassicasterol-derived group, etc. Among these, preferred are sterol-derived groups such as a cholesterol-derived group, a cholestanol-derived group, a lanosterol-derived group, and an ergosterol-derived group, and more preferred are cholesterol-derived groups.
[0056] The hydrocarbon group as the hydrophobic group is not particularly limited, and examples thereof include chain (preferably linear) hydrocarbon groups (preferably alkyl groups) having 8 to 50 carbon atoms (preferably 10 to 30, more preferably 12 to 20).
[0057] The weight-average molecular weight of the modified polysaccharide is not particularly limited as long as it can form gel particles, but is, for example, 5,000 to 2,000,000, preferably 10,000 to 1,000,000, more preferably 20,000 to 500,000, even more preferably 40,000 to 250,000, and still more preferably 80,000 to 125,000.
[0058] The number of hydrophobic groups contained in the modified polysaccharide is not particularly limited as long as the modified polysaccharide can form gel particles, and is, for example, 1 to 10, preferably 1 to 5, per 100 sugar residues that constitute the polysaccharide.
[0059] The hydrophobic group can be linked to the polysaccharide directly or indirectly (eg, via a linker).
[0060] The modified polysaccharide may be, for example, a polysaccharide in which the primary hydroxyl groups of, for example, 1 to 10 (preferably 1 to 5) sugar units per 100 sugar residues constituting the polysaccharide are replaced with a primary hydroxyl group of the formula (II): -O-(CH2) x CONH (CH2) y Preferred is one represented by NH-CO-O-R (II) (wherein R represents a hydrophobic group or a hydrocarbon group having a sterol skeleton; x represents 0 or 1; and y represents any positive integer). y is preferably 1 to 8.
[0061] The modified polysaccharides can be synthesized according to or in accordance with known methods (e.g., International Publication No. WO 00 / 12564). For example, the following method can be mentioned: First, a hydroxyl-containing hydrocarbon or sterol having 12 to 50 carbon atoms is mixed with OCN-R A NCO (in the formula, R A is a hydrocarbon group having 1 to 50 carbon atoms.) to produce an isocyanate group-containing hydrophobic compound in which one molecule of a hydroxyl group-containing hydrocarbon or sterol having 12 to 50 carbon atoms has reacted. The resulting isocyanate group-containing hydrophobic compound is then further reacted with a polysaccharide to produce a hydrophobic group-containing polysaccharide containing a hydrocarbon group having 12 to 50 carbon atoms or a steryl group as the hydrophobic group. The resulting reaction product can be purified with a ketone solvent to produce a highly pure hydrophobic group-containing polysaccharide.
[0062] The modified polysaccharides may be one type alone or a combination of two or more types.
[0063] The mass ratio of the modified polysaccharide to the compound of general formula (1) (mass of modified polysaccharide / mass of the compound of general formula (1)) is preferably 1 or more, more preferably 2 to 20, even more preferably 3 to 10, and even more preferably 3 to 8. By setting the mass ratio within the above range, it becomes possible to exert even more anticancer activity and macrophage polarization activity.
[0064] The complex of the present invention can be a gel particle. "Gel particle" refers to a polymer gel particle having a hydrogel structure. A hydrogel is a three-dimensional network structure formed by crosslinking hydrophilic polymers, which swells upon absorbing water. In the complex of the present invention, which is a gel particle, the modified polysaccharide self-assembles via physical crosslinks formed based on hydrophobic interactions caused by hydrophobic groups to form a three-dimensional network structure. When the complex of the present invention is a gel particle, the compound of general formula (1) is preferably contained inside the gel particle.
[0065] The shape of the complex of the present invention is not particularly limited, but is usually spherical.
[0066] The complex of the present invention is preferably nanosized (preferably a nanogel particle), and its scattering intensity average particle size is, for example, 200 nm or less, preferably 10 to 200 nm, more preferably 20 to 200 nm, even more preferably 60 to 190 nm, still more preferably 80 to 180 nm, and particularly preferably 90 to 160 nm. The particle size can be measured by dynamic light scattering.
[0067] The complex of the present invention can contain other substances in addition to the modified polysaccharide. Examples of the other substances include proteins, peptides, nucleic acids, sugars, low-molecular-weight compounds, high-molecular-weight compounds, inorganic substances, and complexes thereof. More specifically, examples of the other substances include drugs such as adjuvants, cancer antigens, anticancer drugs, and nucleic acid medicines.
[0068] Adjuvants can be selected from inactivated bacterial cells, bacterial cell extracts, nucleic acid lipopolysaccharides, lipopeptides, synthetic low-molecular-weight compounds, etc., and preferably include imidazoquinolines (e.g., R848 and imiquimod), saponins (e.g., QuilA and QS21), STING agonists (e.g., cyclic di-GMP), monophosphoryl lipids, and lipopeptides. Other adjuvants include taxane drugs, anthracycline drugs, JAK / STAT inhibitors, indole deoxygenase (IDO) inhibitors, and tryptophan deoxygenase (TDO) inhibitors. These inhibitors include compounds that antagonize the factor, as well as neutralizing antibodies against the factor.
[0069] Cancer antigens include antigenic polypeptides, preferably antigenic polypeptides. Antigenic polypeptides are antigens or partial peptides thereof that are highly expressed in cancer cells, and in some cases, are expressed only by cancer cells. Antigenic polypeptides can be expressed within cancer cells or on the surface of cancer cells.
[0070] Antigenic polypeptides include, but are not limited to, ERK1, ERK2, MART-1 / Melan-A, gp100, adenosine deaminase binding protein (ADAbp), FAP, cyclophilin b, colorectal-associated antigen (CRC)-C017-1A / GA733, carcinoembryonic antigen (CEA), CAP-1, CAP-2, etv6, AML1, prostate-specific antigen (PSA), PSA-1, PSA-2, PSA-3, prostate-specific membrane antigen (PSMA), T-cell receptor / CD3-zeta chain, C D20, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, MAGE-A12, MAGE-Xp 2 (MAGE-B2), MAGE-Xp3 (MAGE-B3), MAGE-Xp4 (MAGE-B4), MAGE-C1, MAGE-C2, MAGE-C3, MAGE-C4, MAGE-C5, GAGE-1, GAGE-2, GAGE-3, GA GE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8 and GAGE-9, BAGE, RAGE, LAGE-1, NAG, GnT-V, MUM-1, CDK4, tyrosinase, p53, MUC family, HER2 / neu, p21ras, RCAS1, α-fetoprotein, E-cadherin, α-catenin, β-catenin, γ-catenin, p120ctn, gp100Pmel117, PRAME, NY-ESO-1, cdc27, adenomatous polyposis coli protein (APC) , fodrin, connexin 37, Ig idiotype, p15, gp75, GM2 ganglioside, GD2 ganglioside, human papillomavirus protein, Smad family of tumor antigens, lmp-1, P1A, EBV-encoded nuclear antigen (EBNA)-1, brain glycogen phosphorylase, SSX-1, SSX-2 (HOM-MEL-40), SSX-1, SSX-4, SSX-5, SCP-1, CT-7, CD20, c-erbB-2, and partial peptides thereof.
[0071] Examples of anticancer agents include alkylating agents, antimetabolites, microtubule inhibitors, antibiotic anticancer agents, topoisomerase inhibitors, platinum agents, molecular targeted drugs, hormone agents, and biological agents.
[0072] Examples of alkylating agents include cyclophosphamide, ifosfamide, nitrosourea, dacarbazine, temozolomide, nimustine, busulfan, melphalan, procarbazine, and ranimustine.
[0073] Examples of antimetabolites include enocitabine, carmofur, capecitabine, tegafur, tegafur-uracil, tegafur-gimeracil-oteracil potassium, gemcitabine, cytarabine, cytarabine ocfosfate, nelarabine, fluorouracil, fludarabine, pemetrexed, pentostatin, methotrexate, cladribine, doxifluridine, hydroxycarbamide, and mercaptopurine.
[0074] Examples of microtubule inhibitors include alkaloid anticancer drugs such as vincristine, and taxane anticancer drugs such as docetaxel and paclitaxel.
[0075] Examples of antibiotic anticancer agents include mitomycin C, doxorubicin, epirubicin, daunorubicin, bleomycin, actinomycin D, aclarubicin, idarubicin, pirarubicin, peplomycin, mitoxantrone, amrubicin, and zinostatin stimalamer.
[0076] Examples of topoisomerase inhibitors include CPT-11, irinotecan, and nogitecan, which have a topoisomerase I inhibitory effect, and etoposide and sobuzoxane, which have a topoisomerase II inhibitory effect.
[0077] Examples of platinum agents include cisplatin, nedaplatin, oxaliplatin, and carboplatin.
[0078] Examples of hormone agents include dexamethasone, finasteride, tamoxifen, astrozole, exemestane, ethinylestradiol, chlormadinone, goserelin, bicalutamide, flutamide, prednisolone, leuprorelin, letrozole, estramustine, toremifene, fosfestrol, mitotane, methyltestosterone, medroxyprogesterone, and mepitiostane.
[0079] Examples of biologics include interferon α, β, and γ, interleukin 2, ubenimex, dried BCG, and exotoxins. Specifically, exotoxins (proteins) produced by the bacterium Pseudomonas exotoxin (PE) have the enzymatic activity of NAD+-diphthamide-ADP-ribosyl transferase, which inhibits protein synthesis and exerts strong toxicity. To date, PE conjugated to an antibody called CD22 antibody has been approved as an anticancer drug.
[0080] Examples of molecularly targeted drugs include rituximab, alemtuzumab, trastuzumab, cetuximab, panitumumab, imatinib, dasatinib, nilotinib, gefitinib, erlotinib, temsirolimus, bevacizumab, VEGF trap, sunitinib, sorafenib, tosituzumab, bortezomib, gemtuzumab ozogamicin, ibritumomab ozogamicin, ibritumomab tiuxetan, tamibarotene, and tretinoin. In addition to the molecular targeted drugs specified herein, other molecular targeted drugs include immune checkpoint inhibitors such as anti-PD-1 antibodies (e.g., nivolumab and pembrolizumab), anti-PD-L1 antibodies (e.g., atezolizumab, durvalumab, avelumab, and cemiplimab), and anti-CTLA-4 antibodies (e.g., ipilimumab and tremelimumab), inhibitors targeting angiogenesis such as human epidermal growth factor receptor 2 inhibitors, epidermal growth factor receptor inhibitors, Bcr-Abl tyrosine kinase inhibitors, epidermal growth factor tyrosine kinase inhibitors, mTOR inhibitors, and vascular endothelial growth factor receptor 2 inhibitors (α-VEGFR-2 antibodies), various tyrosine kinase inhibitors such as MAP kinase inhibitors, inhibitors targeting cytokines, proteasome inhibitors, and antibody-anticancer drug combinations. These inhibitors also include antibodies.
[0081] A nucleic acid drug is an active pharmaceutical ingredient that is a nucleic acid, and is not particularly limited insofar as it is so.
[0082] The content of the other substance is, for example, 0 to 10,000 parts by mass, 0 to 1,000 parts by mass, 0 to 500 parts by mass, 0 to 100 parts by mass, 0 to 50 parts by mass, or 0 to 10 parts by mass, relative to 100 parts by mass of the compound of general formula (1) and the modified polysaccharide combined.
[0083] In a preferred embodiment, the complex of the present invention can be obtained in a state where it is dissolved in water or a solvent with a small amount of organic solvent (for example, a solvent containing 1% by mass or less, 0.5% by mass or less, 0.2% by mass or less, 0.1% by mass or less, 0.01% by mass or less, or 0.001% by mass or less of the organic solvent relative to 100% by mass of the solvent). The complex of the present invention can preferably be in a state where it is dissolved in water (aqueous solution form).
[0084] The concentration of the compound of general formula (1) in the complex solution of the present invention (particularly a solution using the above-mentioned solvent) is preferably 0.1 mg / mL or more, 0.2 mg / mL or more, 0.4 mg / mL or more, 0.6 mg / mL or more, 0.8 mg / mL or more, or 1.0 mg / mL or more. The upper limit of the concentration is not particularly limited and is, for example, 10 mg / mL, 6 mg / mL, 4 mg / mL, or 2 mg / mL. According to the present invention, a solution containing the compound of general formula (1), which is poorly soluble in water, at a relatively high concentration as described above can be obtained.
[0085] The concentration of the modified polysaccharide in the complex solution of the present invention (particularly a solution using the above-mentioned solvent) is preferably 1 to 30 mg / mL, 2 to 25 mg / mL, 4 to 20 mg / mL, 6 to 15 mg / mL, or 8 to 12 mg / mL.
[0086] The complex of the present invention can be produced, for example, by stirring a solution (Solution 1) containing the compound of general formula (1) and the modified polysaccharide at a relatively low temperature. This method is excellent in terms of increasing the concentration of the compound of general formula (1) in the complex of the present invention.
[0087] The solvent for Solution 1 contains water. Furthermore, in order to dissolve the compound of General Formula (1), the solvent for Solution 1 preferably contains an organic solvent. The organic solvent is not particularly limited as long as it can dissolve the compound of General Formula (1) and is compatible with water, and preferred examples include dimethyl sulfoxide or N,N-dimethylformamide. The water content in the solvent for Solution 1 is preferably 90.0 to 100 v / v%, more preferably 95.0 to 99.5 v / v%, even more preferably 97.0 to 99.0 v / v% or more, and even more preferably 97.5 to 98.5 v / v% or more. The organic solvent content in the solvent for Solution 1 is preferably 0 to 10 v / v%, more preferably 0.5 to 5.0 v / v%, even more preferably 1.0 to 3.0 v / v%, and even more preferably 1.5 to 2.5 v / v%.
[0088] The concentration of the compound of general formula (1) in Solution 1 is preferably 0.05 to 0.8 mg / mL, more preferably 0.1 to 0.4 mg / mL. The concentration of the modified polysaccharide in Solution 1 is preferably 0.2 to 4 mg / mL, more preferably 0.5 to 3 mg / mL. The mass ratio of the modified polysaccharide to the compound of general formula (1) in Solution 1 (mass of modified polysaccharide / mass of compound) is preferably 1 to 20, more preferably 2 to 10, and even more preferably 3 to 7.
[0089] Solution 1 can be obtained by dissolving the compound of general formula (1) and the modified polysaccharide in an organic solvent, followed by adding water.
[0090] The water used for solution 1 may contain a buffer such as a phosphate buffer.
[0091] The temperature of solution 1 during stirring is preferably 1 to 10°C, more preferably 2 to 6°C. The stirring time of solution 1 is preferably 4 to 24 hours, more preferably 6 to 16 hours. By stirring under these conditions, a composite with a more uniform shape and particle size can be obtained.
[0092] After stirring, the mixture can be subjected to a purification treatment, if necessary. Examples of purification treatments include filter filtration and ultrafiltration. Preferably, ultrafiltration is used to concentrate the mixture and remove the organic solvent. This step makes it possible to adjust the mass ratio of the modified polysaccharide to the compound of general formula (1).
[0093] 2. Uses The complex of the present invention has anti-cancer activity and macrophage polarization activity (polarization from M2-like to M1-like). Therefore, the complex of the present invention can be used as an active ingredient of medicines, reagents, etc. (sometimes referred to as "drugs of the present invention" in this specification), specifically as an active ingredient of cancer therapeutic agents, macrophage (preferably TAM) polarization agents, etc.
[0094] The pharmaceutical agent of the present invention is not particularly limited as long as it contains the conjugate of the present invention, and may further contain other components as necessary. The other components are not particularly limited as long as they are pharmaceutically acceptable. The other components include not only components with pharmacological activity but also additives. Examples of additives include bases, carriers, solvents, dispersants, emulsifiers, buffers, stabilizers, excipients, binders, disintegrants, lubricants, thickeners, moisturizers, colorants, fragrances, chelating agents, etc.
[0095] The pharmaceutical agent of the present invention can contain, in addition to the conjugate of the present invention, other substances that may be contained in the conjugate of the present invention (e.g., drugs such as adjuvants, cancer antigens, anticancer drugs, and nucleic acid drugs). Furthermore, the pharmaceutical agent of the present invention can be used in combination with other substances that may be contained in the conjugate of the present invention (e.g., drugs such as adjuvants, cancer antigens, anticancer drugs, and nucleic acid drugs). In particular, as shown in the Examples (Test Example 10) below, the effectiveness of combination with an anti-PD-1 antibody is demonstrated, and combination with an immune checkpoint inhibitor is useful from the perspective of antitumor effect. Examples of such immune checkpoint inhibitors include anti-PD-1 antibodies (e.g., nivolumab, pembrolizumab, etc.), anti-PD-L1 antibodies (e.g., atezolizumab, durvalumab, avelumab, cemiplimab, etc.), and anti-CTLA-4 antibodies (e.g., ipilimumab, tremelimumab, etc.).
[0096] The mode of use of the agent of the present invention is not particularly limited, and an appropriate mode of use can be adopted depending on the type of agent. Depending on the intended use, the agent of the present invention can be used, for example, in vitro (e.g., added to a culture medium for cultured cells) or in vivo (e.g., administered to an animal).
[0097] The target subjects of application of the agents of the present invention are not particularly limited, and examples of mammals include humans, monkeys, mice, rats, dogs, cats, rabbits, pigs, horses, cattle, sheep, goats, and deer. Examples of cells include animal cells. The type of cell is also not particularly limited, and examples include immune cells (preferably macrophages), blood cells, hematopoietic stem and progenitor cells, gametes (sperm, ova), fibroblasts, epithelial cells, vascular endothelial cells, nerve cells, hepatocytes, keratinocytes, muscle cells, epidermal cells, endocrine cells, ES cells, iPS cells, tissue stem cells, and cancer cells. Among these, macrophages are preferred, and TAM is particularly preferred.
[0098] When the drug of the present invention targets cancer, the target cancer is not particularly limited, and examples thereof include leukemia (including chronic lymphocytic leukemia and acute lymphocytic leukemia), lymphoma (including non-Hodgkin's lymphoma, Hodgkin's lymphoma, T-cell lymphoma, B-cell lymphoma, Burkitt's lymphoma, malignant lymphoma, diffuse lymphoma, and follicular lymphoma), myeloma (including multiple myeloma), breast cancer, colon cancer, kidney cancer, stomach cancer, ovarian cancer, pancreatic cancer, cervical cancer, and uterine cancer. Examples of cancers that may be present include endometrial cancer, esophageal cancer, liver cancer, squamous cell carcinoma of the head and neck, skin cancer, malignant melanoma, urinary tract cancer, prostate cancer, choriocarcinoma, pharyngeal cancer, laryngeal cancer, thecoma, male germinoma, endometrial hyperplasia, endometriosis, embryonal tumor, fibrosarcoma, Kaposi's sarcoma, hemangioma, cavernous hemangioma, hemangioblastoma, retinoblastoma, astrocytoma, neurofibroma, oligodendroglioma, medulloblastoma, neuroblastoma, glioma, rhabdomyosarcoma, osteoblastoma, leiomyosarcoma, thyroid sarcoma, and Wilms' tumor.
[0099] The medicament of the present invention may take any dosage form, for example, oral preparations such as tablets (including orally disintegrating tablets, chewable tablets, effervescent tablets, troches, jelly drops, etc.), pills, granules, fine granules, powders, hard capsules, soft capsules, dry syrups, liquids (including drinks, suspensions, syrups), and jellies; and parenteral preparations such as injectable preparations (e.g., drip injections (e.g., intravenous drip preparations), intravenous injections, intramuscular injections, subcutaneous injections, and intradermal injections), topical preparations (e.g., ointments, poultices, and lotions), suppositories, inhalants, eye preparations, eye ointments, nasal drops, ear drops, and liposomes.
[0100] The route of administration of the drug of the present invention is not particularly limited as long as the desired effect can be obtained, and examples thereof include oral administration, enteral administration such as tube feeding and enema administration, and parenteral administration such as intravenous administration, intraarterial administration, intramuscular administration, intracardiac administration, subcutaneous administration, intradermal administration and intraperitoneal administration.
[0101] The content of the active ingredient (the conjugate of the present invention) in the drug of the present invention depends on the mode of use, the subject to which it is applied, the condition of the subject to which it is applied, etc., and is not limited thereto, but can be, for example, 0.0001 to 100% by weight, preferably 0.001 to 50% by weight.
[0102] The dosage of the agent of the present invention when administered to an animal is not particularly limited as long as it is an effective amount that exerts a pharmacological effect, and is generally 0.1 to 1000 mg / kg body weight, preferably 0.5 to 500 mg / kg body weight per day in terms of the weight of the active ingredient, when administered orally, and 0.01 to 100 mg / kg body weight, preferably 0.05 to 50 mg / kg body weight per day in terms of the weight of the active ingredient when administered parenterally. The dosage can be increased or decreased as appropriate depending on the age, pathological condition, symptoms, etc.
[0103] The present invention will be described in detail below based on examples, but the present invention is not limited to these examples.
[0104] Preparation Example 1 Preparation of Cholesterol-Modified Pullulan Cholesterol-modified pullulan (hereinafter referred to as CHP) was prepared by introducing 1.2 cholesterol molecules per 100 monosaccharides into pullulan with a weight-average molecular weight of 100,000 according to the previous report (Macromolecules 1993, 23, 3062-3068).
[0105] Example 1. Encapsulation of various TLR7 and TLR8 agonists in CHP nanogels. We investigated whether nine TLR7 and TLR8 agonists (telratolimod, motolimod, vesatolimod, resiquimod, imiquimod, CL075, CU-CPT17e, CU-CPT9a, and PF-4878691) could be encapsulated in CHP nanogels. CHP was dissolved in 6 M urea in PBS(-), and the compound solution was added. Then, stepwise dialysis was performed against PBS(-).
[0106] <Results> Of the nine compounds, only one (Telratolimod) could be stably encapsulated in CHP nanogel and dissolved.
[0107] <Discussion> The telratolimod concentration in the nanogel formulation obtained in Example 1 was a low concentration of 0.112 mg / ml. Further improvement of the telratolimod concentration was expected to demonstrate sufficient pharmacological efficacy.
[0108] Example 2. Preparation of Telratolimod-Encapsulated CHP Nanogel Telratolimod-encapsulated CHP nanogel (hereinafter referred to as CHP:Telratolimod) was prepared as follows. 160 mg of CHP 80K (NOF) and 32 mg of Telratolimod (ACHEMBLOCK) were mixed and dissolved in 3.2 mL of N,N-dimethylformamide (hereinafter referred to as DMF). The above DMF solution was added to 160 mL of PBS and stirred overnight at 4°C. The filtrate was passed through a 0.8 μm filter and concentrated and purified using a TFF (Pall, MWCO; 30K) to remove the DMF. After recovery, the filtrate was passed through a 0.45 μm filter to obtain a CHP:Telratolimod solution (scattering intensity average particle size: 149 nm, ELSZ-2000ZS, Otsuka Electronics Co., Ltd.). A calibration curve was prepared by HPLC using a telratolimod standard sample (Column: YMC-Pack C4, 150 x 2.0 mm I.D. S-3 μm, 12 nm, flow rate: 0.3 mL / min, 60% B line, A line: 0.1% FA in HO, B line: 0.1% FA in CHCN). The telratolimod concentration in the CHP:telratolimod solution was calculated by decomposing CHP with aqueous sodium periodate and quantifying the resulting aldehyde groups with Schiff's reagent (CHP: 10.2 mg / mL, telratolimod: 1.17 mg / mL).
[0109] <Discussion> The telratolimod concentration in the nanogel formulation obtained using the newly discovered method in Example 2 was 1.17 mg / ml, approximately 10 times higher than that obtained using previous methods. By using this method to create a nanogel formulation of a poorly soluble drug, we were able to successfully increase the drug concentration. The formulation produced in Example 2 was used in the following Test Examples 1-17.
[0110] Test Example 1. Preparation of TAMs derived from human peripheral blood CD14-positive monocytes derived from human peripheral blood that had been cryopreserved in advance were roused from sleep and placed in a 24-well tissue culture plate at 2 x 10 5Cells were seeded per well in 500 μL of basal medium (RPMI, 10% fetal bovine serum, 50 ng / mL M-CSF) and cultured for three days in a 37°C, 5% CO2 incubator. 500 μL of basal medium was then added and cultured for another three days. Subsequently, the medium was replaced with 500 μL of TAM differentiation medium (prepared separately) supplemented with 10% fetal bovine serum, 50 ng / mL IL-4, 50 ng / mL IL-6, 50 ng / mL IL-10, 50 ng / mL IL-13, and 5% human AB type male donor defibrinogen serum (Veritas). The cells were then cultured for two days.
[0111] Test Example 2: Polarization test of human peripheral blood-derived TAM Telratolimod solution or CHP:Telratolimod solution adjusted to a final concentration of 30 μM in telratolimod equivalent was added to the TAM prepared in Test Example 1, incubated for two days, and TNF-α in the culture supernatant was measured by ELISA (BioLegend). The control was a sample to which only medium was added.
[0112] <Results> The results are shown in Table 1. Compared to telratolimod, CHP:telratolimod produced higher TNF-α. This suggests that encapsulation of telratolimod in CHP nanogels allowed for more efficient uptake of telratolimod into TAMs, causing their polarization into M1-like macrophages, resulting in increased TNF-α production.
[0113]
[0114] Test Example 3: Cancer cell phagocytosis test of human peripheral blood-derived TAM HeLa cells were labeled with fluorescent label 1 (CellTracker Green CMTPX Dye, ThermoFisher) for 30 minutes, washed twice with PBS(-), and cultured overnight in medium (RPMI supplemented with 10% fetal bovine serum) containing 1.25 μM doxorubicin.
[0115] TAMs were prepared using the same method as in Test Example 1. Telratolimod or CHP:Telratolimod was added to basal medium at a final concentration of 10 μM in telratolimod equivalent and incubated for two days. After 30 minutes of labeling with fluorescent label 2 (CellTracker Red CMTPX Dye, ThermoFisher), the TAMs were washed twice with PBS(-). The above-mentioned doxorubicin-treated HeLa cells were added at a 50:50 ratio and co-cultured overnight. The cells were then harvested and the number of cells co-positive for fluorescent labels 1 and 2 was counted by flow cytometry. Controls were treated with medium alone.
[0116] <Results> The results are shown in Table 2. Compared to telratolimod, CHP:telratolimod had improved phagocytic activity against HeLa cancer cells. This indicates that telratolimod was more efficiently taken up by TAMs when encapsulated in CHP nanogel, causing polarization into M1-like macrophages, resulting in increased phagocytic activity.
[0117]
[0118] Test Example 4. Measurement of blood concentration transition in a mouse allogeneic tumor transplant model. 6The mouse colon cancer cell line MC38 was administered intradermally to female C57BL / 6JJmsSlc mice. Mice were used 7 days after cell administration. 84.5 μg of CHP:Telratolimod prepared in Example 2 or Telratolimod dissolved in a solubilizing solvent (17.1% polyethylene glycol 300, 4.3% Tween 80, 8.6% polyoxyethylene hydrogenated castor oil) was injected via the tail vein, and blood Telratolimod concentrations were measured. Five mice were administered each group, and blood samples were taken. After each test drug was administered via the tail vein, 20 μL of serum was collected at 1 minute, 30 minutes, 1 hour, 2 hours, and 6 hours. 80 μL of isopropyl alcohol was added and bead-crushed with a 5 mm diameter stainless steel ball for 1 minute. After adding 400 μL of 80% isopropyl alcohol and 20% acetonitrile, the mixture was mixed, sonicated for 3 minutes, and then centrifuged at 12,000 g for 5 minutes to collect the supernatant. The collected supernatant was analyzed by LS-MS / MS to measure telratolimod concentration. A calibration curve was prepared by preparing a 1.17 mg / mL telratolimod standard solution in DMSO, diluting it 10, 20, 100, 200, 1,000, and 2,000 times, and then diluting it 10 times with fetal bovine serum. Cabozantinib (Selleck) was used as an internal standard for calibration.
[0119] <Results> The results are shown in Figure 1. Telratolimod's blood concentration rapidly decreased within 30 minutes after administration, but Telratolimod encapsulated in CHP nanogel remained in the blood for a longer period of time, with its blood half-life being confirmed to be more than four times longer.
[0120] Test Example 5. Measurement of Intratumoral Telratolimod Concentration in a Mouse Allogeneic Tumor Transplant Model Using a mouse allogeneic tumor transplant model prepared in the same manner as in Test Example 4, the CHP:Telratolimod solution containing 84.5 μg of Telratolimod prepared in Example 2 and the Telratolimod solution prepared in Test Example 4 were administered via the tail vein. One hour later, tumors were excised and the intratumoral Telratolimod concentration was measured. Five mice were used per group. 20 μg of excised tumor fragments were added to 80 μL of isopropyl alcohol and bead-crushed with a 5 mm diameter stainless steel ball for 1 minute. Subsequent processing was performed in the same manner as in Test Example 4.
[0121] <Results> The results are shown in Figure 2. When encapsulated in CHP nanogel, Telratolimod's accumulation in tumors increased approximately three-fold.
[0122] Test Example 6. Antitumor Evaluation in a Mouse Allogeneic Tumor Transplant Model (1) MC38 allogeneic tumor transplant models were prepared using the same method as in Test Example 4. On days 7, 9, 11, 14, 16, and 18 after cell transplantation, the CHP:Telratolimod solution prepared in Example 2 and the Telratolimod solution prepared in Test Example 4 were administered via tail vein injection to five mice per group (Telratolimod dose: 84.5 μg). Tumor diameters were measured on days 7, 9, 11, 14, 16, 18, and 19. Tumor volume was calculated by (major diameter × minor diameter × minor diameter) / 2. The same solution as the vehicle for each drug was administered as a negative control. Vehicle 1 refers to the solubilizing solvent used in Test Example 4, and Vehicle 2 refers to PBS(-).
[0123] <Results> The results are shown in Figure 3. In the CHP:Telratolimod group, tumor size remained almost unchanged from the start of drug administration, and by day 19, tumor growth was inhibited by 92% compared to the vehicle control. On the other hand, the Telratolimod group exhibited a 49% tumor growth inhibition effect compared to the vehicle control. This indicates that encapsulation in CHP nanogel dramatically enhanced the antitumor effect of Telratolimod.
[0124] Test Example 7. Evaluation of TAM Polarization in a Mouse Allogeneic Tumor Transplant Model MC38 allogeneic tumor transplant models were prepared using the same method as in Test Example 6. On days 7, 9, and 11 after cell transplantation, the CHP:Telratolimod solution prepared in Example 2 and the Telratolimod solution prepared in Test Example 4 were administered via tail vein injection to five mice per group (Telratolimod dose: 84.5 μg). One day after the final administration, tumors were excised, and macrophages infiltrating the tumors were measured by flow cytometry. Significance tests were performed using one-way ANOVA (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).
[0125] <Results> The results are shown in Figure 4. The expression of iNOS, an M1-like macrophage marker, was significantly elevated in both the telratolimod and CHP:telratolimod groups, with the CHP:telratolimod group showing a more significant increase in iNOS than the telratolimod group. Furthermore, the M2-like macrophage marker ARG1 tended to decrease in both the telratolimod and CHP:telratolimod groups, but was significantly decreased only in the CHP:telratolimod group. These results suggest that the CHP:telratolimod group polarized tumor macrophages from M2-like to M1-like more than the telratolimod group.
[0126] Test Example 8. Evaluation of cytokine release in a mouse allogeneic tumor transplant model 10 6Allograft model mice were used 10 days after intradermal administration of 1000 cells of the mouse colon cancer cell line MC38 into the dorsal skin of female C57BL / 6JJmsSlc mice. Five mice per group were administered 84.5 μg of telratolimod via tail vein injection with either the telratolimod solution prepared in Test Example 4 or the CHP:telratolimod solution prepared in Example 2. Blood was collected two hours later. Serum was collected by centrifugation, and changes in the levels of each cytokine were measured using the LEGENDplex Mouse Inflammation Panel (BioLegend). Significance was tested using one-way ANOVA (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).
[0127] <Results> The results are shown in Figure 5. The telratolimod solution group showed a rapid increase in IL-6, MCP-1, and IFN-β, suggesting the possibility of cytokine release syndrome. On the other hand, these increases were significantly reduced in the CHP:telratolimod group, indicating that cytokine release syndrome was suppressed.
[0128] Test Example 9. Blood test in a mouse allogeneic tumor transplant model 10 6 MC38 mouse colon cancer cell line cells were administered intradermally to the backs of female C57BL / 6JJmsSlc mice. Seven, nine, and eleven days later, 84.5 μg of telratolimod solution prepared in Test Example 4 and CHP:telratolimod solution prepared in Example 2 were administered via tail vein injection to five mice per group. One day after the final administration, blood was collected and changes in red blood cell and reticulocyte counts were measured. Significance was tested using one-way ANOVA (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).
[0129] <Results> The results are shown in Figure 6. A significant decrease in reticulocytes was observed in the telratolimod solution group, whereas no decrease was observed in the CHP:telratolimod solution group. Reticulocytes are an indicator of red blood cell production in the bone marrow, and while the telratolimod solution group suggests bone marrow toxicity, the CHP:telratolimod solution group showed a significant decrease in reticulocytes, suggesting that encapsulation with CHP nanogel prevents bone marrow suppression.
[0130] Test Example 10. Antitumor evaluation of mouse allogeneic tumor transplant model (2) The mouse allogeneic tumor transplant model was 6 Tumors were generated by intradermal injection of the mouse colon cancer cell line CT26 into female BALB / cCrSlc mice. On days 7, 9, 11, 14, 16, and 18 after cell transplantation, the CHP:Telratolimod solution prepared in Example 2 and the Telratolimod solution prepared in Test Example 4 were administered via tail vein injection. Anti-PD-1 antibody (RMP1-14, Bio X Cell) solution was also administered intraperitoneally. Five mice per group were administered the same treatment (42 μg Telratolimod, 100 μg anti-PD-1 antibody) on days 7, 11, 14, and 18 after cell transplantation. Group 1 received both the CHP:Telratolimod solution and the anti-PD-1 antibody. Tumor diameters were measured on days 7, 9, 11, 14, 16, 18, and 21. The tumor volume was calculated by (major axis × minor axis × minor axis) / 2. The negative control was an untreated group.
[0131] <Results> The results are shown in Figure 7. The CHP:Telratolimod group experienced tumor regression from the start of drug administration. On the other hand, the anti-tumor effect of the Telratolimod group was limited, indicating that encapsulation with CHP nanogel dramatically enhanced the anti-tumor effect of Telratolimod. Furthermore, the anti-tumor effect of the anti-PD-1 antibody was also limited, but when CHP:Telratolimod was used in combination with the anti-PD-1 antibody, the tumor completely disappeared. These results indicate that a strong anti-tumor effect can be expected when CHP:Telratolimod is used in combination with cancers in which the anti-tumor effect of anti-PD-1 antibodies is limited (so-called cold tumors).
[0132] Test Example 11. Preparation of M2-like macrophages derived from human peripheral blood CD14-positive monocytes derived from human peripheral blood that had been cryopreserved in advance were roused from sleep and placed in a 24-well tissue culture plate at 2 x 10 5 Cells were seeded at 500 μL per well in 500 μL of basal medium (RPMI, 10% fetal bovine serum, 50 ng / mL M-CSF) and cultured in a 37°C, 5% CO2 incubator for three days. 500 μL of basal medium was added and cultured for another three days. The basal medium was then replaced with 500 μL of M2-like macrophage differentiation medium supplemented with 50 ng / mL IL-4, 50 ng / mL IL-6, 50 ng / mL IL-10, and 50 ng / mL IL-13, and cultured for two days.
[0133] Test Example 12. Polarization test of M2-like macrophages derived from human peripheral blood. Telratolimod solution or CHP:Telratolimod solution adjusted to a final concentration of 3 μM in telratolimod equivalent was added to the M2-like macrophages prepared in Test Example 11 and incubated for one day. TNF-α, IL-1β, IL-6, IL-12p40 (p40 subunit of IL-12), IL-23, and CXCL10 in the culture supernatant were analyzed using a flow cytometer bead assay kit (LEGENDplex TM The control was added with medium alone.
[0134] <Results> The results are shown in Table 3. Compared to telratolimod, CHP:telratolimod resulted in higher production of TNF-α, IL-1β, IL-6, IL-12p40, IL-23, and CXCL10. This suggests that encapsulation of telratolimod in CHP nanogels allows more efficient uptake of telratolimod into M2-like macrophages, causing their polarization into M1-like macrophages, resulting in increased production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12 (p40 subunit), IL-23, and CXCL10) produced by M1-like macrophages.
[0135]
[0136] Test Example 13: Cancer cell phagocytosis test of human peripheral blood-derived M2-like macrophages HeLa cells were labeled with fluorescent label 1 (CellTracker Green CMTPX Dye, ThermoFisher) for 30 minutes, washed twice with PBS(-), and cultured overnight in medium (RPMI supplemented with 10% fetal bovine serum) supplemented with 2.5 μM doxorubicin.
[0137] M2-like macrophages prepared in Test Example 11 were incubated for one day with basal medium containing telratolimod or CHP:telratolimod at a final concentration of 10 μM (telratolimod equivalent). After 30 minutes of labeling with fluorescent label 2 (CellTracker Red CMTPX Dye, ThermoFisher), the cells were washed twice with PBS(-). The M2-like macrophages were then co-cultured overnight with the above-mentioned HeLa cells at a 50:1 ratio. The cells were then harvested and the number of cells co-positive for fluorescent labels 1 and 2 was counted by flow cytometry. Controls were treated with medium alone.
[0138] <Results> The results are shown in Table 4. Compared to telratolimod, CHP:telratolimod had improved phagocytic activity against HeLa cancer cells. This indicates that telratolimod was more efficiently taken up by TAMs when encapsulated in CHP nanogel, causing polarization into M1-like macrophages, resulting in increased phagocytic activity.
[0139]
[0140] Test Example 14. Antitumor evaluation of a mouse allogeneic tumor transplant model (3) Of the CHP:Telratolimod administration group in Test Example 10, mice (n=4) in which tumors had completely regressed by day 21 were continued to be raised, and it was confirmed that tumors had not recurred in all cases up to day 96. After that, on day 97, 10 ... 6 Each mouse colon cancer cell line, CT26, was transplanted, and tumor growth was measured up to day 120. As a control, five mice (BALB / cCrSlc, female) of the same age that had not previously been transplanted with the CT26 cancer cell line were prepared, and 10 6 The cancer cell line CT26 was transplanted and tumor growth was measured.
[0141] <Results> The results are shown in Figure 8. As a control, mice of the same age that had never received the CT26 cancer cell line developed tumors in all cases (Figure 8, bottom). On the other hand, in mice that showed complete regression after the first cancer cell transplant, tumors did not take root in any cases, and the transplanted cancer cells were completely rejected (Figure 8, top). These results indicate that CHP:Telratolimod induces immune memory against cancer cells, suggesting that remission achieved with CHP:Telratolimod may prevent recurrence.
[0142] Test Example 15. Analysis of Tumor-Infiltrating CD8+ T Cells and Natural Killer Cells (NK Cells) in a Mouse Allogeneic Tumor Transplant Model MC38 allogeneic tumor transplant models were prepared using the same method as in Test Example 6. On days 7 and 9 after cell transplantation, five mice were administered the CHP:Telratolimod solution prepared in Example 2 via tail vein injection (Telratolimod dose: 84.5 μg). Five mice were administered no CHP:Telratolimod as a control. Tumors were excised one day after the final administration, and tumor-infiltrating CD8+ T cells and NK cells were detected by flow cytometry. Significance tests were performed using one-way ANOVA.
[0143] <Results> The results are shown in Figure 9. Administration of CHP:Telratolimod significantly increased the number of CD8-positive T cells and NK cells infiltrating into tumors. These results indicate that CHP:Telratolimod has the effect of increasing the infiltration of CD8-positive T cells and NK cells, which are major effector cells involved in anti-tumor activity, into tumors, and suggest that this is one of the mechanisms of action behind the high anti-tumor effect of CHP:Telratolimod in Test Example 6.
[0144] Test Example 16: Analysis of Cancer Antigen-Specific CD8+ T Cells in a Mouse Allogeneic Tumor Transplant Model MC38 allogeneic tumor transplant models were prepared using the same method as in Test Example 6. Five mice were administered the CHP:Telratolimod solution prepared in Example 2 via tail vein injection on days 7, 9, and 12 after cell transplantation (Telratolimod dose: 84.5 μg). Five mice were administered no CHP:Telratolimod via control. One day after the final administration, the spleens were removed to prepare splenocytes. After stimulation with a peptide of MuLV p15E, a cancer antigen expressed in MC38 cells, or a peptide of TRP2, a cancer antigen expressed in melanoma as a negative control, the cells were permeabilized, and CD8+ T cells were analyzed by flow cytometry using an anti-IFN-γ antibody. Significance tests were performed using unpaired t-tests.
[0145] <Results> The results are shown in Figure 10. In mice administered CHP:Telratolimod, the number of CD8+ T cells that became IFN-γ positive upon stimulation with peptide from MuLV p15, a cancer antigen of MC38 cells, was significantly increased compared to the CHP:Telratolimod-untreated group. On the other hand, stimulation with the negative control TRP2 peptide showed no change in the number of CD8+ T cells that became IFN-γ positive compared to the untreated group. These results demonstrate that CHP:Telratolimod is effective in increasing CD8+ T cells that specifically react with MC38 cancer cells, suggesting that this is one of the mechanisms of action behind the strong antitumor effect of CHP:Telratolimod in Test Example 6.
[0146] Test Example 17. Antitumor evaluation in a mouse allogeneic tumor transplant model (4) The mouse allogeneic tumor transplant model was performed using 5 x 10 5 The mouse melanoma cell line B16F10 was administered intradermally to female C57BL / 6NCrSlc mice. On days 7, 9, 11, 14, and 16 after cell transplantation, the CHP:Telratolimod solution prepared in Example 2 was administered via tail vein injection, while the anti-PD-1 antibody (RMP1-14, Bio X Cell) solution and the anti-PD-L1 antibody (10F.9G2, Bio X Cell) solution were administered intraperitoneally. Each group consisted of 10 mice (160 μg of telratolimod, 200 μg of anti-PD-1 antibody and anti-PD-L1 antibody). Groups receiving the combination of CHP:Telratolimod and anti-PD-1 antibody and groups receiving the combination of CHP:Telratolimod and anti-PD-L1 antibody were also evaluated. Tumor diameters were measured on days 7, 9, 11, 14, 16, and 18. The tumor volume was calculated by (major axis × minor axis × minor axis) / 2. The negative control was an untreated group.
[0147] <Results> The results are shown in Figure 11. The CHP:Telratolimod group, anti-PD-1 antibody group, and anti-PD-L1 antibody group all showed an anti-tumor effect of approximately 50%. On the other hand, the group administered anti-PD-1 antibody and anti-PD-L1 antibody in combination with CHP:Telratolimod showed an anti-tumor effect of approximately 75-80%. These results indicate that the combination of CHP:Telratolimod can be expected to have a high anti-tumor effect against cancers for which the anti-tumor effect of anti-PD-1 antibody and anti-PD-L1 antibody is limited (so-called cold tumors).
Claims
1. A modified polysaccharide containing a hydrophobic group, and a polysaccharide represented by the general formula (1): [In the formula: R 1 R represents a linear alkyl group having 12 to 25 carbon atoms. 2 R represents a linear alkyl group having 2 to 8 carbon atoms. 3 represents a linear alkylene group having 2 to 8 carbon atoms.
2. The complex of claim 1, wherein the constituent polysaccharides of said modified polysaccharide include pullulan.
3. The complex of claim 1, wherein the hydrophobic group comprises a hydrophobic group having a sterol backbone.
4. The complex according to claim 1, wherein the weight-average molecular weight of the modified polysaccharide is 5,000 to 2,000,000.
5. The above R 1 is a linear alkyl group having 15 to 19 carbon atoms, 2 is a linear alkyl group having 3 to 5 carbon atoms, and 3 The complex according to claim 1, wherein is a linear alkylene group having 3 to 5 carbon atoms.
6. The conjugate of claim 5, wherein the compound is Telratolimod.
7. The composite of claim 1 which is a gel particle.
8. The composite of claim 7, wherein said compound is contained within said gel particle.
9. The complex according to claim 1, wherein the mass ratio of the modified polysaccharide to the compound (modified polysaccharide mass / compound mass) is 2 to 20.
10. The complex according to claim 1, having a scattering intensity average particle size of 10 to 200 nm.
11. A medicine comprising the complex according to any one of claims 1 to 10.
12. The pharmaceutical composition according to claim 11, which is a cancer treatment agent.
13. The pharmaceutical according to claim 11, which is a macrophage polarizing agent.
14. A conjugate according to any one of claims 1 to 10 or a pharmaceutical agent according to claim 11, used in combination with an immune checkpoint inhibitor.
Citation Information
Patent Citations
High-purity polysaccharide containing hydrophobic groups and process for producing the same
WO2000012564A1
Compositions, formulations, and methods of lipid-modulated immunomodulatory compounds
JP2013534248A
Drug delivery compositions and uses thereof
JP2019530658A
Cancer vaccine preparation
WO2006077724A1
Nanogel / exosome complex and dds
WO2014054588A1
